Semaglutide, a medication widely recognized for its role in treating type 2 diabetes and assisting with weight loss, has been under scrutiny for its potential side effects
provide clear evidence that GLP-1 signaling in the CNS is also linked to the control of peripheral glucose homeostasis by inhibiting noninsulin-mediated glucose uptake by muscle and increasing insulin secretion from the pancreas
These medications have distinct dosing and clinical data that support their use solely for weight loss purposes
Semaglutide (Ozempic, Wegovy) Tirzepatide (Mounjaro, Zepbound) Liraglutide (Victoza) Clinical Studies A February 2026 study found that SGLT2 inhibitors are often associated with a lower 5-year risk of chronic kidney disease progression than GLP-1s, though both offer substantial benefits
IL-1 = interleukin 1 beta
With testosterone replacement therapy, you inject synthetic testosterone